It’s much cheaper to develop cancer drugs than pharmaceutical companies claim, say the authors of a new analysis. According to the analysis of R&D costs associated with ten new cancer medicines and subsequent revenue earned, the return on investment is of a magnitude not seen in other industries. The US study found the median R&D cost for a ...
Already a member?
Enter your email to keep reading.